Rezatapopt Ovarian Cancer Data: p53 Pill Shrinks Tumours in 48% of Platinum-Resistant Patients
PMV Pharmaceuticals' rezatapopt produced a 48% response rate in platinum-resistant ovarian cancer with TP53 Y220C in the pivotal PYNNACLE trial, with an FDA filing planned for Q1 2027.
